HER2 Negative Breast Cancer
Jun 29, 2021
Intellia’s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly’s Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future
A New Dawn for CRISPR, Intellia Edits Cells Inside the Body Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world’s first-ever trial that has their DNA edited through an in...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
